4//SEC Filing
Hyep Ivan 4
Accession 0002034668-25-000010
CIK 0002023658other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 6:42 PM ET
Size
13.7 KB
Accession
0002034668-25-000010
Insider Transaction Report
Form 4
Hyep Ivan
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-21$3.79/sh+605$2,293→ 145,960 total - Exercise/Conversion
Common Stock
2025-11-24$3.79/sh+17,795$67,439→ 163,150 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-21−605→ 115,979 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (605 underlying) - Sale
Common Stock
2025-11-24$18.55/sh−17,795$330,094→ 145,355 total - Sale
Common Stock
2025-11-21$18.15/sh−605$10,981→ 145,355 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−17,795→ 98,184 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (17,795 underlying)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
Related Parties
1- filerCIK 0002034668
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 6:42 PM ET
- Size
- 13.7 KB